Inventor
MORAN EDMUND J
US47 patents
⚠️ This page may combine multiple inventors who share the name “MORAN EDMUND J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
THERAVANCE INC
33 patentsUS6693202B1Feb 17, 2004
Muscarinic receptor antagonists
THERAVANCE INC253 citations99
US6653323B2Nov 25, 2003
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC100 citations99
US6576793B1Jun 10, 2003
β2-adrenergic receptor agonists
THERAVANCE INC115 citations99
US6541669B1Apr 1, 2003
β2-adrenergic receptor agonists
THERAVANCE INC114 citations99
US6747043B2Jun 8, 2004
Alkoxy aryl β2 adrenergic receptor agonists
THERAVANCE INC77 citations98
US6670376B1Dec 30, 2003
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC129 citations98
US7341993B2Mar 11, 2008
Cross-linked glycopeptide—cephalosporin antibiotics
THERAVANCE INC22 citations96
US7279458B2Oct 9, 2007
Cross-linked glycopeptide-cephalosporin antibiotics
THERAVANCE INC50 citations96
US6974797B2Dec 13, 2005
Cross-linked glycopeptide-cephalosporin antibiotics
THERAVANCE INC45 citations96
US6713651B1Mar 30, 2004
β2-adrenergic receptor agonists
THERAVANCE INC49 citations96
US6593497B1Jul 15, 2003
β2-adrenergic receptor agonists
THERAVANCE INC56 citations96
US7067481B2Jun 27, 2006
Cross-linked glycopeptide-cephalosporin antibiotics
THERAVANCE INC41 citations95
US6919482B2Jul 19, 2005
β2-adrenergic receptor agonists
THERAVANCE INC13 citations93
US7332471B2Feb 19, 2008
Cross-linked glycopeptide-cephalosporin antibiotics
THERAVANCE INC21 citations92
US7125892B2Oct 24, 2006
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC16 citations92
US7067482B2Jun 27, 2006
Cross-linked glycopeptide-cephalosporin antibiotics
THERAVANCE INC43 citations92
US6949568B2Sep 27, 2005
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC23 citations92
US7662815B2Feb 16, 2010
Diaryl ether β2 adrenergic receptor agonists
THERAVANCE INC15 citations84
US7317023B2Jan 8, 2008
Diaryl ether β2 adrenergic receptor agonists
THERAVANCE INC10 citations84
US6683115B2Jan 27, 2004
β2-adrenergic receptor agonists
THERAVANCE INC16 citations84
US7217738B2May 15, 2007
β2-adrenergic receptor agonists
THERAVANCE INC6 citations74
US6750241B2Jun 15, 2004
Protein kinase inhibitors
THERAVANCE INC5 citations74
US7105701B2Sep 12, 2006
β2-adrenergic receptor agonists
THERAVANCE INC2 citations63
US6916961B2Jul 12, 2005
β2-adrenergic receptor agonists
THERAVANCE INC3 citations63
US7871997B2Jan 18, 2011
Cephalosporin compounds
THERAVANCE INC1 citations62
US7582765B2Sep 1, 2009
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC2 citations62
US7553971B2Jun 30, 2009
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC1 citations52
US7456203B2Nov 25, 2008
Muscarinic receptor antagonists
THERAVANCE INC1 citations52
US7452995B2Nov 18, 2008
Aryl aniline β2 adrenergic receptor agonists
THERAVANCE INC0 citations52
US7427639B2Sep 23, 2008
β2-adrenergic receptor agonists
THERAVANCE INC0 citations52
US7211695B2May 1, 2007
β2-adrenergic receptor agonists
THERAVANCE INC0 citations52
US7173039B2Feb 6, 2007
Protein kinase inhibitors
THERAVANCE INC1 citations52
US7037912B2May 2, 2006
Protein kinase inhibitors
THERAVANCE INC0 citations52
THERAVANCE BIOPHARMA R&D IP LLC
7 patentsUS10123984B2Nov 13, 2018
Neprilysin inhibitors
THERAVANCE BIOPHARMA R&D IP LLC3 citations84
US11484531B2Nov 1, 2022
Methods for treating chronic obstructive pulmonary disease
THERAVANCE BIOPHARMA R&D IP LLC5 citations80
US10744104B2Aug 18, 2020
Neprilysin inhibitors
THERAVANCE BIOPHARMA R&D IP LLC2 citations73
US12016835B2Jun 25, 2024
Neprilysin inhibitors
THERAVANCE BIOPHARMA R&D IP LLC0 citations63
US11547687B2Jan 10, 2023
Neprilysin inhibitors
THERAVANCE BIOPHARMA R&D IP LLC0 citations63
US12285417B2Apr 29, 2025
Methods for treating chronic obstructive pulmonary disease
THERAVANCE BIOPHARMA R&D IP LLC0 citations58
US12048692B2Jul 30, 2024
Methods for treating chronic obstructive pulmonary disease
THERAVANCE BIOPHARMA R&D IP LLC0 citations58